-transparent.png){kind=logo}
We found a novel platelet aggregating factor in a patient with steroid-responsive immune thrombocytopenic purpura that is associated with defective collagen-induced platelet functions. The aggregating factor and platelet functions were analyzed. The patient, a 58-year-old female, had purpura and prolonged bleeding time despite adequate platelet counts (greater than 140,000/microL) after steroid therapy. The patient's platelets responded normally to all agonists except collagen. Platelet adhesion to collagen fibrils was decreased. The patient's plasma induced irreversible aggregation and ATP release in normal platelet-rich plasma (PRP). This platelet aggregating factor was found in F(ab')2 fragments of the patient's IgG, which caused thromboxane B2 synthesis, elevation of cytoplasmic Ca2+ levels, and phosphorylation of 40 kDa protein in normal platelets. Platelet aggregation by the patient's IgG was inhibited by prostacyclin, dibutyryl cAMP, diltiazem, disodium ethylenediaminetetraacetate, and antimycin A plus iodoacetate, but ADP scavengers, cyclo-oxygenase inhibitors, and heparin had little or no effect. The aggregating activity of the patient's IgG absorbed to and eluted from normal platelets. The patient's Fab fragments did not induce platelet aggregation in eight of ten normal PRP but specifically inhibited aggregation induced by collagen and by the patient's IgG. The major component of an immunoprecipitate made with the patient's IgG from radiolabeled membrane proteins of normal platelet extract had a 62 kDa mol wt, while no such precipitate appeared in extracts of the patient's platelets. These results indicated that platelet aggregation by the patient's IgG was induced by the reaction of an antibody with a specific antigen on the normal platelet membrane through stimulus-response coupling. This antigen may be a collagen receptor on the platelet, most likely a polypeptide of 62 kDa under reducing condition. The defect of collagen-induced aggregation of the patient's platelets seemed to be due to alteration of the membrane protein related to this putative collagen receptor.
T Sugiyama, and
M Okuma, and
F Ushikubi, and
S Sensaki, and
K Kanaji, and
H Uchino
June 1971,
Thrombosis et diathesis haemorrhagica,
T Sugiyama, and
M Okuma, and
F Ushikubi, and
S Sensaki, and
K Kanaji, and
H Uchino
January 1979,
American journal of hematology,
T Sugiyama, and
M Okuma, and
F Ushikubi, and
S Sensaki, and
K Kanaji, and
H Uchino
January 1992,
American journal of hematology,
T Sugiyama, and
M Okuma, and
F Ushikubi, and
S Sensaki, and
K Kanaji, and
H Uchino
May 1996,
Acta obstetricia et gynecologica Scandinavica,
T Sugiyama, and
M Okuma, and
F Ushikubi, and
S Sensaki, and
K Kanaji, and
H Uchino
July 1983,
Pathology,
T Sugiyama, and
M Okuma, and
F Ushikubi, and
S Sensaki, and
K Kanaji, and
H Uchino
May 1984,
Drug intelligence & clinical pharmacy,
T Sugiyama, and
M Okuma, and
F Ushikubi, and
S Sensaki, and
K Kanaji, and
H Uchino
April 2004,
Journal of thrombosis and haemostasis : JTH,
T Sugiyama, and
M Okuma, and
F Ushikubi, and
S Sensaki, and
K Kanaji, and
H Uchino
November 1995,
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,
T Sugiyama, and
M Okuma, and
F Ushikubi, and
S Sensaki, and
K Kanaji, and
H Uchino
September 1977,
The Journal of laboratory and clinical medicine,
T Sugiyama, and
M Okuma, and
F Ushikubi, and
S Sensaki, and
K Kanaji, and
H Uchino
April 1975,
Experientia,
